Definium Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Feb 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 26, 2026
DFTX$35.39+6.4%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| December 31, | ||
|---|---|---|
| (in thousands, except share amounts) | 2025 | 2024 |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $257,837 | $273,741 |
| Short-term investments | 153,756 | — |
| Prepaid and other current assets | 7,727 | 7,879 |
| Total current assets | 419,320 | 281,620 |
| Goodwill | 19,918 | 19,918 |
| Other non-current assets | 862 | 613 |
| Total assets | $440,100 | $302,151 |
| Liabilities and Shareholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $5,347 | $2,010 |
| Accrued expenses | 20,446 | 12,829 |
| 2022 USD Financing Warrants | 40,905 | 24,010 |
| Total current liabilities | 66,698 | 38,849 |
| Credit facility, long-term | 40,579 | 21,854 |
| Other non-current liabilities | 496 | — |
| Total liabilities | 107,773 | 60,703 |
| Commitments and contingencies (Note 11) | ||
| Shareholders' equity: | ||
| Common shares, no par value, unlimited authorized as of December 31, 2025 and 2024, respectively; 98,776,265 and 75,100,763 issued and outstanding as of December 31, 2025 and 2024, respectively | — | — |
| Additional paid-in capital | 913,914 | 639,508 |
| Accumulated other comprehensive income | 1,085 | 819 |
| Accumulated deficit | (582,672) | (398,879) |
| Total shareholders' equity | 332,327 | 241,448 |
| Total liabilities and shareholders' equity | $440,100 | $302,151 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.